Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngeneā€™s platform for fully integrated therapeutic discovery and development across large and small molecules.Ā 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support theirĀ Ā R&DĀ Ā goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

In Vitro Eye Irritation or Serious Eye Damage Test : Reconstructed human Cornea-like Epithelium (RhCE)

In Vitro Eye Irritation or Serious Eye Damage Test : Reconstructed human Cornea-like Epithelium (RhCE)

The in vitro eye irritation test is used to evaluate the eye hazard potential of a test chemical based on its ability to induce cytotoxicity in a RhCE tissue construct as measured by the tetrazolium dye.

Test model EpiOcular Tissues
Replicates N=2 tissues per test condition
Assay controls Negative control: Ultrapure water
Positive control: Methyl acetate
Exposure time 6 hours (Ā±0.25 h) ā€“ Solids
30 min (Ā±2 min) ā€“ Liquids
50 Ī¼L or 50 mg of test material per tissue
Test item quantity 0.5 ml or 500 mg
End point MTT Tissue viability assay
Data delivery % relative viability Ā± SD
Timeline 15 days

Acceptable OD value for EpiDerm model:

  • Lower acceptance limit: ā‰„ 0.8
  • Upper acceptance limit: ā‰¤ 2.8
Mean tissue viability (%) Data prediction
ā‰¤ 60% Irritant (I)
> 60% Non-irritant (NI)

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details